BridgeBio Oncology Therapeutics, Inc. Cash Flow Quality Index
BridgeBio Oncology Therapeutics, Inc. cash flow quality index. BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow Quality Index of -0.04x as of December 2024. Operating cash flow of $-87.86K is below net income of $1.95 Million, suggesting accrual-heavy earnings not yet converted to cash. See BBOT financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BridgeBio Oncology Therapeutics, Inc. (2024–2024)
Cash flow quality index of BridgeBio Oncology Therapeutics, Inc. from 2024 to 2024. Historical Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BridgeBio Oncology Therapeutics, Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
BridgeBio Oncology Therapeutics, Inc. Cash Flow Quality Index by Year (2024–2024)
BridgeBio Oncology Therapeutics, Inc. cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for BridgeBio Oncology Therapeutics, Inc.. For the full cash flow conversion analysis, see BBOT operating cash flow.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | $-763.82K | $7.60 Million | — |